Phase 1 First-in-Human Multi-Region clinical trial of ORM-1153 in participants with relapsed or refractory acute myeloid leukemia (AML) or other hematological malignancies with CD123 expression
Not yet recruiting
The goal of this Phase 1 clinical trial is to understand whether a new experimental treatment, called ORM-1153, will be a safe and possibly effective treatment option for participants with blood cancers such as Acute Myeloid Leukemia (AML) which have a particular protein (called …
Phase 1 • Sponsor: Orum Therapeutics USA, Inc.
Last updated Sep 09, 2026 18:10 UTC